Rasheed S, Li Z, Xu D, Kovacs A
Department of Pathology, University of Southern California, School of Medicine 90032-3626, USA.
Am J Obstet Gynecol. 1996 Jul;175(1):122-9. doi: 10.1016/s0002-9378(96)70261-2.
The purpose of this study was to establish virologic or molecular criteria for evaluating the rate of transmission of human immunodeficiency virus type 1 and for defining the role of virus burden in the development of gynecologic diseases in human immunodeficiency virus-infected women.
Paired samples of blood and cervicovaginal secretions from 63 human immunodeficiency virus-seropositive women were evaluated for cell-free and cell-associated virus load by several methods, including quantitative cultures and reverse transcription polymerase chain reaction.
All women showed evidence of virus infection in both blood and cervicovaginal secretions by a combination of in vitro culture and molecular detection methods. The CD4+ cell counts in these women ranged from < 200/microliter to > 500/microliter. Blood plasma of 26% women (12/46) did not show detectable levels of human immunodeficiency virus ribonucleic acid by reverse transcription polymerase chain reaction (< 10(2)/100 microliters). These same women had significant amounts of human immunodeficiency virus in the cell-free cervicovaginal secretions (10(2) to 10(5) copies per 100 microliters). In contrast, 17% (8/46) women with significant quantity of human immunodeficiency virus ribonucleic acid in the blood plasma had negative results for human immunodeficiency virus in the cervicovaginal secretions. Further, treatment of women with the antiviral drug zidovudine did not change the human immunodeficiency virus-1 detection rate in plasma ribonucleic acid but showed significant reduction in the ability to detect human immunodeficiency virus ribonucleic acid in cell-free cervicovaginal secretions (p = 0.036).
We conclude that the replication kinetics of human immunodeficiency virus in the blood and cervicovaginal cells are unrelated, independent events. Further, there is no correlation between the virus load or the CD4+ cell counts in the blood and the presence or absence of quantifiable human immunodeficiency virus in cervicovaginal secretions.
本研究的目的是建立病毒学或分子标准，以评估1型人类免疫缺陷病毒的传播率，并确定病毒载量在人类免疫缺陷病毒感染女性妇科疾病发展中的作用。
通过多种方法，包括定量培养和逆转录聚合酶链反应，对63名人类免疫缺陷病毒血清阳性女性的配对血液和宫颈阴道分泌物样本进行无细胞和细胞相关病毒载量评估。
通过体外培养和分子检测方法相结合，所有女性的血液和宫颈阴道分泌物中均显示出病毒感染的证据。这些女性的CD4+细胞计数范围为<200/微升至>500/微升。26%的女性（12/46）血浆通过逆转录聚合酶链反应未检测到人类免疫缺陷病毒核糖核酸水平（<10(2)/100微升）。这些女性的无细胞宫颈阴道分泌物中存在大量人类免疫缺陷病毒（每100微升10(2)至10(5)拷贝）。相比之下，17%（8/46）血浆中人类免疫缺陷病毒核糖核酸含量较高的女性宫颈阴道分泌物中人类免疫缺陷病毒检测结果为阴性。此外，用抗病毒药物齐多夫定治疗女性并未改变血浆核糖核酸中人类免疫缺陷病毒-1的检测率，但显示无细胞宫颈阴道分泌物中检测人类免疫缺陷病毒核糖核酸的能力显著降低（p = 0.036）。
我们得出结论，人类免疫缺陷病毒在血液和宫颈阴道细胞中的复制动力学是不相关的独立事件。此外，血液中的病毒载量或CD4+细胞计数与宫颈阴道分泌物中是否存在可量化的人类免疫缺陷病毒之间没有相关性。
